En Chile, no existen estudios nacionales que evaluen la relacion entre la expresion de PTEN en
glioblastoma y el tiempo de sobrevida, aunque fue evaluada la expresion en cancer ovarico asociado a endometriosis por Castiblanco et al.
Glioblastoma multiforme, also known as grade IV astrocytoma, is a malignant grade IV brain tumor that rapidly spreads within the brain cells and can also infect the nearby cells.
'Our research provides more information about the markers which can signal the presence of
glioblastoma - and the fact we've been able to identify ones that are associated with extracellular vesicles, suggests that there could be a way to use bodily fluids to test for the tumour in future.'
AEO is a patented metabolite and is the company's lead clinical development candidate for
Glioblastoma Multiforme.
The discovery presents an opportunity to find out if new therapeutic approaches can stop
glioblastoma at its earliest stages of initial formation or recurrence, Lu said.
"It felt important to me to support the National Brain Appeal's fundraising to work towards making this available to NHS patients with
glioblastoma."
The research of Duke University makes good use of poliovirus which can kill neurons specifically.[4] Based on this mechanism, the poliovirus can be applied to treat
glioblastoma. Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO) recognizes the CD155 overexpressed by recurrent glioma as its target and attacks glioma cells.
What are the treatment options for
glioblastoma? Since 2005, a combination of surgery, chemotherapy, and radiation has been the standard of care for
glioblastoma, according to neurosurgeon Eric Holland, director of Seattle Translational Tumor Research and senior vice president and director of the Human Biology Division at Hutch.
Keywords:
Glioblastoma, Tumour Treating Fields, Alternating Electric Fields, Progression Free Survival, Overall Survival
"There is currently no cure for
glioblastoma, and the development of new treatments is a very important unmet need," said Oblato President and Chief Executive Officer Won S.
Kazia is developing GDC-0084 as a potential treatment for the primary form of brain cancer,
glioblastoma multiforme.